Janus Henderson Group
ALLO icon

Janus Henderson Group’s Allogene Therapeutics ALLO Stock Holding History

Janus Henderson Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-102,349
Closed -$219K – 2484
2024
Q4 		$219K Hold
102,349
– – ﹤0.01% 2397
2024
Q3 		$287K Hold
102,349
– – ﹤0.01% 2291
2024
Q2 		$238K Buy
102,349
+65,851
+180% +$194K ﹤0.01% 2318
2024
Q1 		$163K Hold
36,498
– – ﹤0.01% 2459
2023
Q4 		$117K Buy
36,498
+25
+0.1% +$71 ﹤0.01% 2516
2023
Q3 		$116K Buy
36,473
+71
+0.2% +$311 ﹤0.01% 2493
2023
Q2 		$180K Sell
36,402
-31
-0.1% -$168 ﹤0.01% 2474
2023
Q1 		$180K Buy
36,433
+20,596
+130% +$132K ﹤0.01% 2519
2022
Q4 		$99.5K Sell
15,837
-15,839
-50% -$147K ﹤0.01% 2334
2022
Q3 		$342K Buy
31,676
+15,603
+97% +$212K ﹤0.01% 2129
2022
Q2 		$184K Buy
16,073
+426
+3% +$3.78K ﹤0.01% 2332
2022
Q1 		$143K Buy
+15,647
New +$163K ﹤0.01% 2508
2021
Q4 		– Sell
-7,795
Closed -$200K – 2545
2021
Q3 		$200K Buy
+7,795
New +$185K ﹤0.01% 2081

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group's ALLO Position: Q1 2025 in Review

Janus Henderson Group sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 102,349 shares — an estimated $219K sold.

Janus Henderson Group first reported a position in ALLO in Q3 2021 and held it in 13 quarters. The position peaked at $342K in Q3 2022. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Janus Henderson Group reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Janus Henderson Group sold 102,349 Allogene Therapeutics shares in Q1 2025, an estimated $219K.
  • Janus Henderson Group first reported a position in Allogene Therapeutics in Q3 2021 and held it in 13 quarters.
  • Janus Henderson Group's Allogene Therapeutics position peaked at $342K in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Janus Henderson Group's 13F filing for Q1 2025, filed 15 May 2025.